Interpace Biosciences Stock Cash Flow From Operations
| IDXGDelisted Stock | USD 1.09 0.02 1.87% |
Interpace Biosciences fundamentals help investors to digest information that contributes to Interpace Biosciences' financial success or failures. It also enables traders to predict the movement of Interpace OTC Stock. The fundamental analysis module provides a way to measure Interpace Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Interpace Biosciences otc stock.
Interpace |
Interpace Biosciences OTC Stock Cash Flow From Operations Analysis
Interpace Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Interpace Biosciences Cash Flow From Operations | (8.72 M) |
Most of Interpace Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Interpace Biosciences has (8.72 Million) in Cash Flow From Operations. This is 101.65% lower than that of the Health Care Providers & Services sector and 103.8% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.9% higher than that of the company.
Interpace Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in cash flow from operations category among related companies.
Interpace Fundamentals
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 4.27 M | ||||
| Shares Owned By Insiders | 28.12 % | ||||
| Number Of Shares Shorted | 47.35 K | ||||
| Price To Earning | (1.07) X | ||||
| Price To Book | 10.04 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 41.31 M | ||||
| Gross Profit | 17.95 M | ||||
| EBITDA | (9.12 M) | ||||
| Net Income | (14.94 M) | ||||
| Cash And Equivalents | 1.86 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 9.44 M | ||||
| Debt To Equity | 6.55 % | ||||
| Current Ratio | 0.61 X | ||||
| Book Value Per Share | (14.51) X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 5.16 M | ||||
| Total Asset | 38.43 M | ||||
| Retained Earnings | (172.59 M) | ||||
| Working Capital | (4.21 M) | ||||
| Current Asset | 19.16 M | ||||
| Current Liabilities | 23.37 M | ||||
| Z Score | -4.6 | ||||
| Net Asset | 38.43 M |
About Interpace Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Interpace Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Interpace Biosciences' short interest history, or implied volatility extrapolated from Interpace Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |